Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
AURA
Upturn stock ratingUpturn stock rating

Aura Biosciences Inc (AURA)

Upturn stock ratingUpturn stock rating
$7.8
Delayed price
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

02/07/2025: AURA (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Analysis of Past Performance

Type Stock
Historic Profit -59.61%
Avg. Invested days 20
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 02/07/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 389.62M USD
Price to earnings Ratio -
1Y Target Price 21.83
Price to earnings Ratio -
1Y Target Price 21.83
Volume (30-day avg) 125609
Beta 0.33
52 Weeks Range 6.63 - 12.38
Updated Date 02/9/2025
52 Weeks Range 6.63 - 12.38
Updated Date 02/9/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.73

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -30.22%
Return on Equity (TTM) -50.99%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 234328434
Price to Sales(TTM) -
Enterprise Value 234328434
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -5.68
Shares Outstanding 49951500
Shares Floating 34354121
Shares Outstanding 49951500
Shares Floating 34354121
Percent Insiders 3.09
Percent Institutions 82.84

AI Summary

Aura Biosciences Inc. - A Comprehensive Overview

Company Profile:

History and Background:

Aura Biosciences Inc. (AURA) is a clinical-stage biotechnology company founded in 2019. Headquartered in Cambridge, Massachusetts, AURA focuses on developing novel therapies for patients with solid tumors. The company leverages its proprietary STING agonist platform to create therapies that activate the innate immune system to fight cancer.

Core Business Areas:

  • STING Agonist Platform: AURA's core technology platform revolves around the development of STING (Stimulator of Interferon Genes) agonists, which are molecules that activate the innate immune system.

  • Therapeutic Development: AURA currently focuses on developing two clinical-stage STING agonists:

    • AUNP-12: Designed as a local treatment for melanoma, AUNP-12 is currently in a Phase 1b clinical trial.
    • AUNP-19: This intratumoral STING agonist is being tested in a Phase 1b clinical trial for the treatment of head and neck cancer.

Leadership Team and Corporate Structure:

  • CEO: Elisabet de los Pinos
  • President and Chief Medical Officer: Dr. Barbara Fox
  • Chief Scientific Officer: Dr. Peter Van Vlasselaer
  • AURA's leadership team comprises experienced professionals with expertise in drug development, clinical research, and finance.

Top Products and Market Share:

  • AUNP-12 and AUNP-19 are currently in clinical trials and not yet commercially available. Therefore, AURA does not have any marketed products or market share data.
  • AURA's STING agonist platform holds significant promise for the future development of innovative cancer therapies.

Total Addressable Market:

  • The global market for cancer immunotherapy was valued at approximately $171.3 billion in 2022 and is projected to reach $314.7 billion by 2029.
  • AURA's STING agonists have the potential to target a significant portion of this market, particularly in the melanoma and head and neck cancer segments.

Financial Performance:

  • As a clinical-stage company, AURA does not currently generate significant revenue.
  • Net income, profit margins, and EPS are also not applicable at this stage.
  • AURA's financial performance is primarily driven by research and development expenses related to its clinical trials.

Dividends and Shareholder Returns:

  • AURA is a pre-revenue company and does not currently pay dividends.
  • Shareholder returns are primarily driven by stock price performance, which has been volatile in recent months.

Growth Trajectory:

  • AURA has experienced significant growth in its clinical development activities in recent years.
  • Positive data from ongoing clinical trials for AUNP-12 and AUNP-19 could fuel further growth in the future.
  • AURA's future growth potential is also dependent on its ability to secure funding for further clinical development and commercialization efforts.

Market Dynamics:

  • The cancer immunotherapy market is rapidly evolving, with significant investment in new technologies and clinical trials.
  • AURA's STING agonists have the potential to compete with other immunotherapies, such as checkpoint inhibitors.
  • AURA's success will depend on its ability to demonstrate the efficacy and safety of its STING agonists in clinical trials and differentiate itself from competitors.

Competitors:

  • Major competitors in the STING agonist space include:
    • Enobia Pharma (ENOB)
    • ImmunoGen (IMGN)
    • Oncosec Medical (ONCS)
    • Mustang Bio (MBIO)
  • AURA's competitive advantages include its proprietary STING agonist platform, experienced leadership team, and promising clinical data.

Potential Challenges and Opportunities:

Challenges:

  • Clinical trial risks and uncertainties remain a significant challenge for AURA.
  • Competition from established players in the cancer immunotherapy market is intense.
  • Funding future development and commercialization efforts will be crucial for AURA's success.

Opportunities:

  • Positive clinical trial results could lead to significant market opportunities for AURA.
  • Partnerships with larger pharmaceutical companies could provide AURA with additional funding and expertise.
  • The rapidly evolving cancer immunotherapy market presents significant opportunities for innovation and differentiation.

Recent Acquisitions:

AURA has made no acquisitions in the last three years.

AI-Based Fundamental Rating:

  • Currently, AURA does not have a public AI-based rating due to its pre-revenue status and lack of sufficient data for analysis.

Sources and Disclaimers:

  • Information for this analysis was gathered from sources such as Aura Biosciences' website, SEC filings, and industry reports.
  • Please note that this overview is for informational purposes only and should not be considered investment advice. Investors should conduct their due diligence before making any investment decisions.

Conclusion:

Aura Biosciences is a promising clinical-stage biotechnology company with a novel STING agonist platform and a promising pipeline of cancer immunotherapy candidates. However, as a pre-revenue company, AURA faces significant risks and uncertainties. Investors should carefully consider the company's financial position, clinical development progress, competitive landscape, and potential opportunities and challenges before making any investment decisions.

About Aura Biosciences Inc

Exchange NASDAQ
Headquaters Boston, MA, United States
IPO Launch date 2021-10-29
Founder, CEO, President & Director Dr. Elisabet de los Pinos Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 88
Full time employees 88

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmette"guérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​